Skip to main content

Tempus AI, Inc. (TEM) Stock Price & Market Analysis

TEM · NASDAQ · Medical - Healthcare Information Services

Delayed

$69.26

▼ -$6.64(-8.74%)11:46 AM ET - vs previous close

Quote as of Nov 13, 2026, 11:46 AM EST

NASDAQ regular-session quote as of Nov 13, 2026, 11:46 AM EST.

Last session11%
$68.48L Nov 13 '26$75.72H Nov 13 '26
52-week range59%
$40.77L Jul 28 '26$89.09H Sep 29 '26
Long-term rangesAvailable history
Available history(2024-06-14)57%
$22.89L Jun 25 '24$104.32H Oct 9 '25

Historical range: 2024-06-14–2026-11-13. Earlier trading may not be included.

Loading price chart…

Data dates

PriceDelayedLast traded

FundamentalsLast checked

AnalystLast checked

NewsLatest item

Reported fundamentals

TEM financial overview

Annual revenue

USD 1.27B

Sales for the fiscal year ended Dec 31, 2025. This is not trailing twelve-month revenue.

Revenue change

+83.4%

Change versus the fiscal year ended Dec 31, 2024.

Net profit margin

-19.3%

Net income divided by revenue for the fiscal year ended Dec 31, 2025. This is not the trailing margin.

These reported results describe the business’s recent scale and profitability. Compare cash generation and valuation before forming an investment view; historical growth is not a forecast.

Company · ProfileAbout Tempus AI, Inc. (TEM)Sector, leadership, and how Tempus AI, Inc. earns its revenue.

Tempus AI, Inc.

NASDAQ · TEM · US

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

Company overview as of Nov 13, 2026.

Sector
Healthcare
Industry
Medical - Healthcare Information Services
Headquarters
Chicago, IL, United States
Country
US
Employees
3,800
CEO
Mr. Eric P. Lefkofsky J.D.
Exchange
NASDAQ
Business model & operating resultsExplore business exposure, reported operating measures and the figures behind growth and profitability claims.

Company website ↗

Narrative versus numbers

Demand is expanding

Supporting observation: 23.1%

Year-over-year growth in the latest quarter. This differs from the fiscal-year revenue change shown above. · Source timestamp: Sep 30, 2026

Growth produces accounting profit

Contradicting observation: -12.5%

Net margin; the source did not supply a reporting period. Do not compare this reading with the quarterly or fiscal-year figures above. A positive margin does not establish cash generation. · Source timestamp: Nov 13, 2026, 11:46 AM EST

The business generates cash after investment

Contradicting observation: USD -122K

Latest free cash flow from the statement feed. It is not a forecast and may cover a different period from the fiscal-year figures above. · Source timestamp: Sep 30, 2026

These are explicit tests of individual claims, not an overall bull/bear rating. Demand growth can coexist with valuation, concentration and financing risk.

Operating measures

Revenue
$411.54Mquarter ended Sep 30, 2026
Operating margin
-13.8%quarter ended Sep 30, 2026
EPS
-$0.08quarter ended Sep 30, 2026
Capital expenditure
$9.34Mquarter ended Sep 30, 2026
Free cash flow
-$122,000.00quarter ended Sep 30, 2026
Free cash flow margin
-0.0%quarter ended Sep 30, 2026
Revenue growth year over year
23.1%quarter ended Sep 30, 2026
Competitors & comparisonsCompare industry peers, reporting periods and related funds. Business mix and valuation bases may differ.
Valuation & fund comparisonsExplore dated peer valuations, growth comparisons and related funds.

Governance & sustainability

Find proxy statements and annual reports

Data sources: Financial Modeling Prep · Finnhub · SEC Companyfacts · Yahoo Finance

Market data is for information only and is not trading advice. Prices and fundamentals may be delayed, reflect an earlier observation, be incomplete, or be revised. Read the data methodology or the full disclaimer.
Research tools
Regular session

Regular hours: 9:30 AM–4:00 PM America/New_York

Next open: 2026-11-16 · 9:30 AM America/New_York

Exchange calendar includes scheduled holidays and early closes. Extended-session prices appear separately only when supplied by the quote source.